Molecular Partners: Funding, Investors & Team (Sep 2026)
Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics, a new class of custom-built drugs for medical challenges other modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zürich, Switzerland and Concord, MA, USA.
Molecular Partners has raised $20.0M across 1 funding round on record, the most recent an undisclosed round of $20.0M announced in Oct 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Molecular Partners Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Molecular Partners Funding Rounds
Molecular Partners Founders and Leadership Team
No contact details are on record for this team yet.
Molecular Partners Funding Compared to Other Biotechnology Startups
Molecular Partners' latest round of $20.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Molecular Partners in Biotechnology and Zürich
Companies Similar to Molecular Partners
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Molecular Partners Funding FAQs
What does Molecular Partners do?
Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics, a new class of custom-built drugs for medical challenges other modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zürich, Switzerland and Concord, MA, USA.
How much funding has Molecular Partners raised?
Molecular Partners has raised $20.0M across 1 round on record. The most recent is an undisclosed round of $20.0M announced in Oct 2024.
When did Molecular Partners last raise funding?
Molecular Partners' most recent funding round on record is an undisclosed round of $20.0M, announced in Oct 2024.
Who founded Molecular Partners?
FundedIQ lists Michael Tobias Stumpp (Founder) at Molecular Partners.
Where is Molecular Partners headquartered?
Molecular Partners is based in Zürich, Zurich, Switzerland.
How many employees does Molecular Partners have?
Molecular Partners is in the 51-100 employee band.
How does Molecular Partners' funding compare to other Biotechnology startups?
Molecular Partners' latest round of $20.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Molecular Partners Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Molecular Partners is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.